OXYBUTYNIN CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oxybutynin Chloride, and when can generic versions of Oxybutynin Chloride launch?
Oxybutynin Chloride is a drug marketed by Chartwell Rx, Lannett Co Inc, Pharm Assoc, Pharmobedient Cnsltg, Accord Hlthcare, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Impax Pharms, Norvium Bioscience, Osmotica Pharm Us, Rubicon, Unique, Zydus Pharms, Abhai Llc, Avet Lifesciences, Beximco Pharms Usa, Hibrow Hlthcare, Leading, Novast Labs, Novitium Pharma, Quantum Pharmics, Rising, Strides Pharma, Teva Pharms Usa, Trupharma, Upsher Smith Labs, Usl Pharma, and Watson Labs. and is included in thirty-four NDAs.
The generic ingredient in OXYBUTYNIN CHLORIDE is oxybutynin chloride. There are sixteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxybutynin Chloride
A generic version of OXYBUTYNIN CHLORIDE was approved as oxybutynin chloride by TEVA PHARMS USA on November 14th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXYBUTYNIN CHLORIDE?
- What are the global sales for OXYBUTYNIN CHLORIDE?
- What is Average Wholesale Price for OXYBUTYNIN CHLORIDE?
Summary for OXYBUTYNIN CHLORIDE
| US Patents: | 0 |
| Applicants: | 29 |
| NDAs: | 34 |
| Finished Product Suppliers / Packagers: | 39 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 23 |
| Patent Applications: | 1,693 |
| Drug Prices: | Drug price information for OXYBUTYNIN CHLORIDE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OXYBUTYNIN CHLORIDE |
| What excipients (inactive ingredients) are in OXYBUTYNIN CHLORIDE? | OXYBUTYNIN CHLORIDE excipients list |
| DailyMed Link: | OXYBUTYNIN CHLORIDE at DailyMed |
See drug prices for OXYBUTYNIN CHLORIDE
Recent Clinical Trials for OXYBUTYNIN CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Seoul National University Hospital | Phase 2 |
| Il-Yang Pharm. Co., Ltd. | Phase 2 |
| Alliance for Clinical Trials in Oncology | Phase 2 |
Pharmacology for OXYBUTYNIN CHLORIDE
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for OXYBUTYNIN CHLORIDE
Paragraph IV (Patent) Challenges for OXYBUTYNIN CHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GELNIQUE | Gel | oxybutynin chloride | 10% | 022204 | 1 | 2014-06-19 |
US Patents and Regulatory Information for OXYBUTYNIN CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hibrow Hlthcare | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 211062-001 | Feb 6, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Unique | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 206121-001 | May 27, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Strides Pharma | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 208165-001 | Dec 17, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Quantum Pharmics | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 072296-001 | Dec 8, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 071655-001 | Nov 14, 1988 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Osmotica Pharm Us | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 078503-003 | Feb 4, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
